Nurix Therapeutics Inc

Research Nurix Therapeutics Inc (NRIX) on Bullrun: market cap USD 2.79B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 2.79B.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 83.98M-USD 264.46M-USD 263.47Mn/a-3.05USD 246.96MUSD 55.73MUSD 538.75M
FY2024USD 54.55M-USD 193.57M-USD 181.86Mn/a-2.88USD 110.00MUSD 28.30MUSD 526.99M
FY2023USD 76.99M-USD 143.95M-USD 89.77Mn/a-2.65USD 54.63MUSD 30.61MUSD 200.49M
FY2022USD 38.63M-USD 180.36M-USD 172.05Mn/a-3.71USD 64.47MUSD 14.51MUSD 303.70M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 2.79Bn/an/an/a
20252025-12-31USD 1.93Bn/an/an/a
20242024-12-31USD 1.43Bn/an/an/a
20232023-12-29USD 502.78Mn/an/an/a
20222022-12-30USD 517.95Mn/an/an/a
20212021-12-31USD 1.29Bn/an/an/a

About Nurix Therapeutics Inc

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Nurix Therapeutics Inc's market cap?

Nurix Therapeutics Inc's market capitalization is USD 2.79B.

What does Nurix Therapeutics Inc do?

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.